FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808059539> ?p ?o ?g. }

• W2808059539 endingPage "902" @default.
• W2808059539 startingPage "895" @default.
• W2808059539 abstract "Background DFP-10917 is a cytotoxic deoxycytidine analogue that causes DNA fragmentation, G2/M–phase arrest, and apoptosis. This agent has been shown to have antitumor activity against colorectal cancer (CRC) in preclinical studies and to be tolerable in patients. The purpose of our phase II trial was to evaluate the safety, efficacy and pharmacogenomics of DFP-10917 as well as DNA damage studies in patients with advanced CRC refractory to cytotoxic chemotherapy. Methods In this single-arm, Simon two-stage, phase II trial, patients with chemotherapy-refractory advanced CRC received 2.0 mg/m2/day DFP-10917 via 14-day continuous infusion. Enrollment criteria included age ≥ 18 years, Eastern Cooperative Oncology Group status of 0 or 1, and adequate organ function. The primary endpoint was 3-month progression-free survival, defined as the proportion of patients who did not have progressive disease or death within 3 months of starting therapy. All patients who received any amount of DFP-10917 were included in the safety analysis. DNA damage study was assessed by comet assay. Results Of 28 patients initially enrolled, 26 received DFP-10917. Three patients (12%) were progression free at 3 months. The median progression-free survival was 1.3 months (95% confidence interval, 1.3–1.6 months). There were no complete or partial responses. Most patients (n = 20, 77%) had progressive disease, and only six (23%) had stable disease at any time. The trial was terminated according to the pre-planned stopping rule. The most frequent (≥5%) medication-related grade 3 or higher adverse events were neutropenia (n = 10, 38%), fatigue (n = 4, 15%), anemia (n = 3, 12%), and leukopenia (n = 3, 12%). DNA strand-breaks were detected after infusion (medians of % tail intensity were 2.89 and 12.64 on day 1 and day 15, respectively, p < 0.001, sign test). Conclusion Overall, single-agent DFP-10917 did not show meaningful antitumor activity in chemotherapy-refractory advanced CRC. The safety profile of DFP-10917 was tolerable and similar to that observed in earlier clinical studies." @default.
• W2808059539 created "2018-06-21" @default.
• W2808059539 creator A5005121092 @default.
• W2808059539 creator A5006348751 @default.
• W2808059539 creator A5015750678 @default.
• W2808059539 creator A5019320471 @default.
• W2808059539 creator A5074334218 @default.
• W2808059539 date "2018-06-13" @default.
• W2808059539 modified "2023-09-27" @default.
• W2808059539 title "Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer" @default.
• W2808059539 cites W1550111394 @default.
• W2808059539 cites W1869406861 @default.
• W2808059539 cites W1984858612 @default.
• W2808059539 cites W2029409133 @default.
• W2808059539 cites W2037662715 @default.
• W2808059539 cites W2057899441 @default.
• W2808059539 cites W2086347868 @default.
• W2808059539 cites W2139210450 @default.
• W2808059539 cites W2139248078 @default.
• W2808059539 cites W2147834058 @default.
• W2808059539 cites W2163699185 @default.
• W2808059539 cites W2225175526 @default.
• W2808059539 cites W2235523093 @default.
• W2808059539 cites W2330814896 @default.
• W2808059539 cites W2411875523 @default.
• W2808059539 cites W242040007 @default.
• W2808059539 cites W2668520732 @default.
• W2808059539 cites W2784098500 @default.
• W2808059539 cites W4243574300 @default.
• W2808059539 doi "https://doi.org/10.1007/s10637-018-0615-8" @default.
• W2808059539 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6136955" @default.
• W2808059539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29948357" @default.
• W2808059539 hasPublicationYear "2018" @default.
• W2808059539 type Work @default.
• W2808059539 sameAs 2808059539 @default.
• W2808059539 citedByCount "1" @default.
• W2808059539 countsByYear W28080595392023 @default.
• W2808059539 crossrefType "journal-article" @default.
• W2808059539 hasAuthorship W2808059539A5005121092 @default.
• W2808059539 hasAuthorship W2808059539A5006348751 @default.
• W2808059539 hasAuthorship W2808059539A5015750678 @default.
• W2808059539 hasAuthorship W2808059539A5019320471 @default.
• W2808059539 hasAuthorship W2808059539A5074334218 @default.
• W2808059539 hasBestOaLocation W28080595392 @default.
• W2808059539 hasConcept C121608353 @default.
• W2808059539 hasConcept C126322002 @default.
• W2808059539 hasConcept C141071460 @default.
• W2808059539 hasConcept C142424586 @default.
• W2808059539 hasConcept C143998085 @default.
• W2808059539 hasConcept C203092338 @default.
• W2808059539 hasConcept C2776694085 @default.
• W2808059539 hasConcept C2778822529 @default.
• W2808059539 hasConcept C31760486 @default.
• W2808059539 hasConcept C526805850 @default.
• W2808059539 hasConcept C535046627 @default.
• W2808059539 hasConcept C71924100 @default.
• W2808059539 hasConcept C86803240 @default.
• W2808059539 hasConcept C87355193 @default.
• W2808059539 hasConcept C90924648 @default.
• W2808059539 hasConceptScore W2808059539C121608353 @default.
• W2808059539 hasConceptScore W2808059539C126322002 @default.
• W2808059539 hasConceptScore W2808059539C141071460 @default.
• W2808059539 hasConceptScore W2808059539C142424586 @default.
• W2808059539 hasConceptScore W2808059539C143998085 @default.
• W2808059539 hasConceptScore W2808059539C203092338 @default.
• W2808059539 hasConceptScore W2808059539C2776694085 @default.
• W2808059539 hasConceptScore W2808059539C2778822529 @default.
• W2808059539 hasConceptScore W2808059539C31760486 @default.
• W2808059539 hasConceptScore W2808059539C526805850 @default.
• W2808059539 hasConceptScore W2808059539C535046627 @default.
• W2808059539 hasConceptScore W2808059539C71924100 @default.
• W2808059539 hasConceptScore W2808059539C86803240 @default.
• W2808059539 hasConceptScore W2808059539C87355193 @default.
• W2808059539 hasConceptScore W2808059539C90924648 @default.
• W2808059539 hasIssue "5" @default.
• W2808059539 hasLocation W28080595391 @default.
• W2808059539 hasLocation W28080595392 @default.
• W2808059539 hasLocation W28080595393 @default.
• W2808059539 hasLocation W28080595394 @default.
• W2808059539 hasOpenAccess W2808059539 @default.
• W2808059539 hasPrimaryLocation W28080595391 @default.
• W2808059539 hasRelatedWork W1980324865 @default.
• W2808059539 hasRelatedWork W2032110158 @default.
• W2808059539 hasRelatedWork W2465617904 @default.
• W2808059539 hasRelatedWork W2528057197 @default.
• W2808059539 hasRelatedWork W2590956466 @default.
• W2808059539 hasRelatedWork W2593294044 @default.
• W2808059539 hasRelatedWork W2708905130 @default.
• W2808059539 hasRelatedWork W3171492215 @default.
• W2808059539 hasRelatedWork W4205934876 @default.
• W2808059539 hasRelatedWork W4306253774 @default.
• W2808059539 hasVolume "36" @default.
• W2808059539 isParatext "false" @default.
• W2808059539 isRetracted "false" @default.
• W2808059539 magId "2808059539" @default.
• W2808059539 workType "article" @default.